vs

Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and Apyx Medical Corp (APYX). Click either name above to swap in a different company.

Apyx Medical Corp is the larger business by last-quarter revenue ($19.2M vs $11.9M, roughly 1.6× ASCENT INDUSTRIES CO.). Apyx Medical Corp runs the higher net margin — -6.8% vs -8.8%, a 2.0% gap on every dollar of revenue. On growth, Apyx Medical Corp posted the faster year-over-year revenue change (34.7% vs 13.3%). ASCENT INDUSTRIES CO. produced more free cash flow last quarter ($-196.0K vs $-2.8M). Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs -34.9%).

Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.

Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.

ACNT vs APYX — Head-to-Head

Bigger by revenue
APYX
APYX
1.6× larger
APYX
$19.2M
$11.9M
ACNT
Growing faster (revenue YoY)
APYX
APYX
+21.4% gap
APYX
34.7%
13.3%
ACNT
Higher net margin
APYX
APYX
2.0% more per $
APYX
-6.8%
-8.8%
ACNT
More free cash flow
ACNT
ACNT
$2.6M more FCF
ACNT
$-196.0K
$-2.8M
APYX
Faster 2-yr revenue CAGR
APYX
APYX
Annualised
APYX
36.8%
-34.9%
ACNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACNT
ACNT
APYX
APYX
Revenue
$11.9M
$19.2M
Net Profit
$-1.0M
$-1.3M
Gross Margin
14.6%
62.6%
Operating Margin
-21.0%
0.1%
Net Margin
-8.8%
-6.8%
Revenue YoY
13.3%
34.7%
Net Profit YoY
-1.2%
71.9%
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACNT
ACNT
APYX
APYX
Q4 25
$11.9M
$19.2M
Q3 25
$19.7M
$12.9M
Q2 25
$18.7M
$11.4M
Q1 25
$24.7M
$9.4M
Q4 24
$10.5M
$14.2M
Q3 24
$20.9M
$11.5M
Q2 24
$21.5M
$12.1M
Q1 24
$28.0M
$10.2M
Net Profit
ACNT
ACNT
APYX
APYX
Q4 25
$-1.0M
$-1.3M
Q3 25
$-2.1M
$-2.0M
Q2 25
$6.3M
$-3.8M
Q1 25
$-2.3M
$-4.2M
Q4 24
$-1.0M
$-4.6M
Q3 24
$-6.2M
$-4.7M
Q2 24
$-926.0K
$-6.6M
Q1 24
$-5.5M
$-7.6M
Gross Margin
ACNT
ACNT
APYX
APYX
Q4 25
14.6%
62.6%
Q3 25
29.7%
64.4%
Q2 25
26.1%
62.3%
Q1 25
19.3%
60.1%
Q4 24
24.3%
63.0%
Q3 24
14.4%
60.5%
Q2 24
13.1%
61.7%
Q1 24
8.3%
58.1%
Operating Margin
ACNT
ACNT
APYX
APYX
Q4 25
-21.0%
0.1%
Q3 25
-4.1%
-6.5%
Q2 25
-14.4%
-22.6%
Q1 25
-4.2%
-32.4%
Q4 24
-25.4%
-21.4%
Q3 24
-9.4%
-31.6%
Q2 24
-8.6%
-45.7%
Q1 24
-15.5%
-64.6%
Net Margin
ACNT
ACNT
APYX
APYX
Q4 25
-8.8%
-6.8%
Q3 25
-10.6%
-15.4%
Q2 25
33.7%
-33.2%
Q1 25
-9.3%
-44.0%
Q4 24
-9.8%
-32.5%
Q3 24
-29.5%
-40.9%
Q2 24
-4.3%
-54.0%
Q1 24
-19.7%
-74.0%
EPS (diluted)
ACNT
ACNT
APYX
APYX
Q4 25
$-0.11
Q3 25
$-0.22
Q2 25
$0.65
Q1 25
$-0.23
Q4 24
$-0.11
Q3 24
$-0.61
Q2 24
$-0.09
$-0.19
Q1 24
$-0.54
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACNT
ACNT
APYX
APYX
Cash + ST InvestmentsLiquidity on hand
$57.6M
$31.7M
Total DebtLower is stronger
$37.5M
Stockholders' EquityBook value
$87.0M
$14.5M
Total Assets
$111.9M
$66.8M
Debt / EquityLower = less leverage
2.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACNT
ACNT
APYX
APYX
Q4 25
$57.6M
$31.7M
Q3 25
$58.0M
$25.1M
Q2 25
$60.5M
$29.3M
Q1 25
$14.3M
$31.0M
Q4 24
$16.1M
$31.7M
Q3 24
$8.5M
$28.0M
Q2 24
$3.6M
$32.7M
Q1 24
$1.3M
$37.3M
Total Debt
ACNT
ACNT
APYX
APYX
Q4 25
$37.5M
Q3 25
$37.5M
Q2 25
$37.5M
Q1 25
$37.5M
Q4 24
$0
$37.5M
Q3 24
$37.5M
Q2 24
Q1 24
Stockholders' Equity
ACNT
ACNT
APYX
APYX
Q4 25
$87.0M
$14.5M
Q3 25
$87.1M
$5.8M
Q2 25
$89.7M
$7.3M
Q1 25
$91.2M
$10.5M
Q4 24
$93.5M
$14.2M
Q3 24
$94.7M
$11.0M
Q2 24
$101.0M
$14.7M
Q1 24
$102.0M
$20.3M
Total Assets
ACNT
ACNT
APYX
APYX
Q4 25
$111.9M
$66.8M
Q3 25
$119.9M
$57.4M
Q2 25
$122.6M
$58.2M
Q1 25
$152.5M
$60.2M
Q4 24
$147.3M
$64.8M
Q3 24
$148.6M
$60.7M
Q2 24
$158.2M
$65.4M
Q1 24
$161.0M
$70.7M
Debt / Equity
ACNT
ACNT
APYX
APYX
Q4 25
2.58×
Q3 25
6.41×
Q2 25
5.17×
Q1 25
3.57×
Q4 24
0.00×
2.64×
Q3 24
3.40×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACNT
ACNT
APYX
APYX
Operating Cash FlowLast quarter
$266.0K
$-2.5M
Free Cash FlowOCF − Capex
$-196.0K
$-2.8M
FCF MarginFCF / Revenue
-1.7%
-14.6%
Capex IntensityCapex / Revenue
3.9%
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.1M
$-9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACNT
ACNT
APYX
APYX
Q4 25
$266.0K
$-2.5M
Q3 25
$1.3M
$-3.5M
Q2 25
$-1.4M
$-1.2M
Q1 25
$-700.0K
$-702.0K
Q4 24
$8.8M
$-2.9M
Q3 24
$3.4M
$-4.4M
Q2 24
$2.2M
$-4.3M
Q1 24
$263.0K
$-6.3M
Free Cash Flow
ACNT
ACNT
APYX
APYX
Q4 25
$-196.0K
$-2.8M
Q3 25
$695.0K
$-4.1M
Q2 25
$-1.5M
$-1.5M
Q1 25
$-1.0M
$-757.0K
Q4 24
$8.4M
$-3.2M
Q3 24
$3.1M
$-4.6M
Q2 24
$1.9M
$-4.6M
Q1 24
$25.0K
$-6.4M
FCF Margin
ACNT
ACNT
APYX
APYX
Q4 25
-1.7%
-14.6%
Q3 25
3.5%
-31.5%
Q2 25
-8.3%
-13.2%
Q1 25
-4.1%
-8.0%
Q4 24
80.6%
-22.4%
Q3 24
15.1%
-40.0%
Q2 24
9.1%
-38.0%
Q1 24
0.1%
-62.2%
Capex Intensity
ACNT
ACNT
APYX
APYX
Q4 25
3.9%
1.4%
Q3 25
3.1%
4.0%
Q2 25
0.8%
2.3%
Q1 25
1.3%
0.6%
Q4 24
3.7%
1.7%
Q3 24
1.3%
1.3%
Q2 24
1.0%
2.4%
Q1 24
0.9%
0.3%
Cash Conversion
ACNT
ACNT
APYX
APYX
Q4 25
Q3 25
Q2 25
-0.22×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACNT
ACNT

Other$6.1M52%
Transferred At Point In Time$5.7M48%

APYX
APYX

Segment breakdown not available.

Related Comparisons